Undifferentiated Sarcoma of the Liver
Lauren T. May(Monash University), Margaret E. Macy(Children's Hospital Colorado), Edythe A. Albano(Office of the Director), Megan K. Dishop(Office of the Director), Timothy Garrington(Children's Hospital Colorado), Michael Wang(St. Joseph Health System)
Cited by 38
Related Papers
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263